EUVIMEDEUVIMED entdecken
Systematische Übersicht

Abstract TH102: Cardiovascular Benefits of Aldosterone-Targeted Therapies Beyond Blood Pressure Reduction in Primary Aldosteronism: A Systematic Review

Drashti Thakkar, Narasimman Gurusamy, Luigi X Cubeddu

Hypertension · 2026-10 · 83 (Suppl_1)

DOI: 10.1161/hyp.83.suppl_1.th102 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Hypertension, 2026-10. Verfasst von Drashti Thakkar und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary aldosteronism is associated with substantially greater cardiovascular morbidity and mortality than essential hypertension, independent of blood pressure. Excess aldosterone contributes to myocardial fibrosis, left ventricular hypertrophy, endothelial dysfunction, arterial stiffness, and vascular remodeling. We systematically reviewed the evidence evaluating cardiovascular benefits of aldosterone-targeted therapies beyond blood pressure reduction in patients with primary aldosteronism.

Methods

A systematic review of PubMed and Embase was performed. Eligible studies included adults with primary aldosteronism treated with adrenalectomy, spironolactone, eplerenone, or other aldosterone-directed therapies and reporting cardiovascular outcomes beyond blood pressure control. Outcomes included cardiac remodeling, vascular remodeling, endothelial function, arterial stiffness, major adverse cardiovascular events (MACE), and mortality.

Results

Eight studies involving approximately 4,736 patients met the inclusion criteria, with follow-up ranging from 3 months to 7.4 years. At baseline, patients with primary aldosteronism had a significantly higher prevalence of cardiovascular events than patients with essential hypertension (35% vs 11%; OR 4.61, 95% CI 2.38-8.95). Aldosterone-targeted therapies produced cardiovascular benefits independent of blood pressure reduction. Long-term treatment reduced carotid intima-media thickness following adrenalectomy (0.956±0.140 to 0.866±0.130 mm; P

Zitieren

APA

Thakkar, D., Gurusamy, N., & Cubeddu, L. X. (2026). Abstract TH102: Cardiovascular Benefits of Aldosterone-Targeted Therapies Beyond Blood Pressure Reduction in Primary Aldosteronism: A Systematic Review. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.th102

Vancouver

Thakkar D, Gurusamy N, Cubeddu LX. Abstract TH102: Cardiovascular Benefits of Aldosterone-Targeted Therapies Beyond Blood Pressure Reduction in Primary Aldosteronism: A Systematic Review. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.th102

BibTeX
@article{Thakkar2026,
  author = {Thakkar, Drashti and Gurusamy, Narasimman and Cubeddu, Luigi X},
  title = {Abstract TH102: Cardiovascular Benefits of Aldosterone-Targeted Therapies Beyond Blood Pressure Reduction in Primary Aldosteronism: A Systematic Review},
  journal = {Hypertension},
  year = {2026},
  volume = {83},
  number = {Suppl_1},
  doi = {10.1161/hyp.83.suppl_1.th102}
}
Kostenlos starten →